Company

Management Management

  • Management
  • Scientific Advisory Board
Samyang  has built a team of innovative and successful drug developers whose deep collective experience spans drug discovery, research, and development at leading biotechnology and pharmaceutical companies Samyang  has built a team of innovative and successful drug developers whose deep collective experience spans drug discovery, research, and development at leading biotechnology and pharmaceutical companies
President Eom, Tae-Woong Profile Image
Tae-Ung Eom
President

After graduating with a degree in chemistry from Sogang University, the President, Tae-Ung Eom, worked in the strategic planning field for 35 years as part of the Samyang Group and led a number of major M&A and C&D as a strategic planning specialist within Samyang Group. Since 2015, he has been serving as the President of Samyang Biopharmaceuticals Corp., Inc. and is proceeding with the plan to create and implement a new 2020 vision.

Chief Stategy Officer의 Helen  Lee Profile Image.
HyunJung Helen Lee
Chief Strategy Officer

Hyun Jung Helen Lee, MD, MHCM is a Gynecologist by training and has been working on the development of anti-cancer drugs for 15 years in Global, the US and the Asia. Prior to joining Samyang as the CSO and CMO, she served as the Global Head of Solid Tumor Clinical Development at Shire in the US. She has held various executive positions at Baxalta, Eli Lilly and Pfizer. After graduating from Yonsei University College of Medicine, she completed her residency training at Severance Hospital, and later, earned her master's degree in Health Care Management at Harvard School of Public Health. She has also been serving as the President of Samyang Biopharm USA Inc. since October 2018.

Biopharmaceutical Research Director Min-hyo Seo Profile Image.
Helen Cho
Vice President / R&D Center

Helen Cho, Ph.D. received her Bachelor’s degree in biochemistry at Yonsei University, Master degree in Biological Engineering at Korean Advanced Institute of Science and Technology and a Ph.D in molecular biology and biochemistry at the University of Medicine and Dentistry of New Jersey in the U.S. Following her postdoctoral training at the Salk Institute, Dr. Cho joined Global Pharmaceutical Company, Pfizer where she devoted her multi-disciplinary knowledge to developing immunotherapy based regimens for the treatment of cancer. As an Association Research Fellow, she led the research and development of cancer vaccine- and oncolytic virus-based immune-oncology combination therapies into early phase clinical trials. Recently, Dr. Cho joined Samyang Biopharmaceuticals Corporation as the director of R&D.

Chief Biopharmaceutical Officer Yong-jin Lee Profile Image.
Yong-Jin Lee
Vice President / Pharmaceutical Business

Yong-Jin Lee received his Bachelor’s degree in Biology at Korea University, and his MBA at Dongguk University. Since 2001, he has joined Samyang and led Regulatory Affairs and Oncology Sales teams. He was recognized and awarded by the Minister of Ministry of Food and Drug Safety and Minister of Ministry of Health and Welfare for his expertise in sales and marketing. He is a director of both domestic and overseas pharmaceutical business at Samyang.

Chief MD Officer Jae–Doo Lee Profile Image.
Jae-Do Lee
Vice President / MD Business

Jae-Do Lee, received his Bachelor's and Master's degree in chemical engineering from Hanyang University. He joined Samyang in 1993 and is currently working in the field of medical devices. After the release of the medical suture product in 1996, he was in charge of the overseas sales of the medical suture, and contributed greatly to establishing the company's global business base for the suture. Currently, he is directing sales, marketing and the MD plant in the medical device division.

  • School of Engineering and Applied Sciences, Harvard University
  • The Biologic Therapeutics Center and Radiation Oncology, Washington University, School of Medicine
  • Professor, Graduate School of Medical Science and Engineering, KAIST
  • Professor, KU-KIST school, Korea University, Principal research scientist, KIST
  • Eshelman School of Pharmacy, University of North Carolina at Chapel Hill.
  • David. Mooney
    David. Mooney
  • David T. Curiel, M.D.
    David T. Curiel, M.D.
  • School of Engineering and App ied Sciences, Harvard University
  • Director of the Biologic Therapeutics Center and Distinguished Professor of Radiation Oncology, Washington University School of Medicine
  • Director of the Gene Therapy Center and the Division of Human Gene Therapy, University of Alabama at Birmingham
  • Eui-Cheol Shin, M.D.
    Eui-Cheol Shin, M.D.
  • In-San Kim, M.D.
    In-San Kim, M.D.
  • Assistant Professor, Associate Professor, Graduate School of Medical Science and Engineering, KAIST
  • Professor, KU-KIST school, Korea University, Principal research scientist, KIST